| 7209- | EGb 761, | Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review |
| - | Review, | AD, | NA |
| 7208- | EGb 761, | EGb 761 reduces Ca2+ influx and apoptosis after pentylenetetrazole treatment in a neuroblastoma cell line |
| - | in-vitro, | Nor, | SH-SY5Y |
| 7203- | EGb 761, | Ginkgo biloba extract EGb 761 is safe and effective in the treatment of mild dementia - a meta-analysis of patient subgroups in randomised controlled trials |
| - | Review, | AD, | NA |
| 7202- | EGb 761, | Ginkgo biloba leaf extract EGb 761® for the treatment of various diseases: Overview of systematic reviews |
| - | Review, | AD, | NA |
| 7200- | EGb 761, | PCA, | Optimized Ginkgo biloba extract EGb 761®: boosted therapeutic benefits with minimized CYP enzyme interference |
| 7196- | EGb 761, | Ginkgo biloba extract EGb 761 in patients with dementia and a history of cerebral infarction-meta-analysis of pooled data from randomised clinical trials |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 7225- | EGb 761, | Efficacy and safety of Ginkgo biloba standardized extract in the treatment of vascular cognitive impairment: a randomized, double-blind, placebo-controlled clinical trial |
| - | Trial, | AD, | NA |
| 7237- | EGb 761, | Ginkgo biloba Extract Mechanism Inhibits Hepatocellular Carcinoma through the Nuclear Factor-κB/p53 Signaling Pathway |
| - | in-vitro, | HCC, | HepG2 |
| 7232- | EGb 761, | Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial |
| - | Trial, | AD, | NA |
| 7231- | EGb 761, | Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials |
| - | Review, | AD, | NA |
| 7230- | EGb 761, | Ginkgo biloba extract (EGb 761) promotes peripheral nerve regeneration and neovascularization after acellular nerve allografts in a rat model |
| - | in-vivo, | Nor, | NA |
| 7229- | EGb 761, | Meta-analysis of the efficacy and safety of Ginkgo biloba extract for the treatment of dementia |
| - | Review, | AD, | NA |
| 7228- | EGb 761, | Current Perspectives on the Beneficial Role of Ginkgo biloba in Neurological and Cerebrovascular Disorders |
| - | Review, | AD, | NA |
| 7235- | EGb 761, | Stabilization of Mitochondrial Membrane Potential and Improvement of Neuronal Energy Metabolism by Ginkgo Biloba Extract EGb 761 |
| - | in-vitro, | AD, | NA |
| 7239- | EGb 761, | Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis |
| - | Review, | AD, | NA |
| 7222- | EGb 761, | Ginkgo biloba extract EGb 761® in the symptomatic treatment of mild-to-moderate dementia: a profile of its use |
| - | Review, | AD, | NA |
| 7240- | EGb 761, | EGb 761 protects liver mitochondria against injury induced by in vitro anoxia/reoxygenation |
| - | in-vitro, | Nor, | NA |
| 7220- | EGb 761, | Ginkgo Biloba Extract Inhibits Metastasis and ERK/Nuclear Factor kappa B (NF-κB) Signaling Pathway in Gastric Cancer |
| - | vitro+vivo, | GC, | SGC-7901 |
| 7219- | EGb 761, | Ginkgo biloba Prevents Oxidative Stress-Induced Apoptosis Blocking p53 Activation in Neuroblastoma Cells |
| - | in-vitro, | Nor, | SK-N-BE |
| - | Trial, | Nor, | NA |
| 7236- | EGb 761, | Neuroprotective effects of bilobalide, a component of the Ginkgo biloba extract (EGb 761), in gerbil global brain ischemia |
| - | in-vivo, | Stroke, | NA |
| 3721- | EGb 761, | Ginkgo biloba Extract in Alzheimer’s Disease: From Action Mechanisms to Medical Practice |
| - | Review, | AD, | NA |
| 3428- | EGCG, | Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex |
| - | Review, | Var, | NA |
| 3230- | EGCG, | Green Tea Polyphenol Epigallocatechin 3-Gallate, Contributes to the Degradation of DNMT3A and HDAC3 in HCT 116 Human Colon Cancer Cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 |
| 3229- | EGCG, | Epigallocatechin-3-gallate (EGCG) Alters Histone Acetylation and Methylation and Impacts Chromatin Architecture Profile in Human Endothelial Cells |
| - | in-vitro, | Nor, | HMEC | - | in-vitro, | Nor, | HUVECs |
| 3228- | EGCG, | Targeting fibrotic signaling pathways by EGCG as a therapeutic strategy for uterine fibroids |
| 3227- | EGCG, | Epigallocatechin-3-gallate treatment to promote neuroprotection and functional recovery after nervous system injury |
| - | NA, | Nor, | NA |
| 3226- | EGCG, | Epigallocatechin-3-gallate, a green-tea polyphenol, suppresses Rho signaling in TWNT-4 human hepatic stellate cells |
| - | in-vitro, | Nor, | NA |
| 3225- | EGCG, | Epigallocatechin‐3‐Gallate Ameliorates Diabetic Kidney Disease by Inhibiting the TXNIP/NLRP3/IL‐1β Signaling Pathway |
| - | in-vitro, | Nor, | NA | - | in-vivo, | Nor, | NA |
| 3224- | EGCG, | Epigallocatechin-3-Gallate Prevents Acute Gout by Suppressing NLRP3 Inflammasome Activation and Mitochondrial DNA Synthesis |
| - | in-vitro, | Nor, | NA |
| 3223- | EGCG, | The Effects of Green Tea Catechins in Hematological Malignancies |
| - | Review, | AML, | NA |
| 3222- | EGCG, | Epigallocatechin gallate and mitochondria—A story of life and death |
| - | Review, | Nor, | NA |
| 3217- | EGCG, | Epigallocatechin-3-gallate promotes angiogenesis via up-regulation of Nfr2 signaling pathway in a mouse model of ischemic stroke |
| - | in-vivo, | Stroke, | NA |
| 3221- | EGCG, | EGCG upregulates phase-2 detoxifying and antioxidant enzymes via the Nrf2 signaling pathway in human breast epithelial cells |
| - | in-vitro, | Nor, | MCF10 |
| 3220- | EGCG, | Dual Roles of Nrf2 in Cancer |
| - | in-vitro, | Lung, | A549 |
| 3219- | EGCG, | Nano-chemotherapeutic efficacy of (−) -epigallocatechin 3-gallate mediating apoptosis in A549 cells: Involvement of reactive oxygen species mediated Nrf2/Keap1signaling |
| - | in-vitro, | Lung, | A549 |
| 3218- | EGCG, | Comparative efficacy of epigallocatechin-3-gallate against H2O2-induced ROS in cervical cancer biopsies and HeLa cell lines |
| - | in-vitro, | Cerv, | HeLa |
| 3241- | EGCG, | Epigallocatechin gallate triggers apoptosis by suppressing de novo lipogenesis in colorectal carcinoma cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | HUH7 |
| 3231- | EGCG, | Epigallocatechin-3-gallate restores mitochondrial homeostasis impairment by inhibiting HDAC1-mediated NRF1 histone deacetylation in cardiac hypertrophy |
| - | in-vitro, | Nor, | NA |
| 3232- | EGCG, | (−)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer׳s disease model mice by upregulating neprilysin expression |
| - | in-vivo, | AD, | NA |
| 3233- | EGCG, | Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways |
| - | in-vitro, | Cerv, | HeLa |
| 3234- | EGCG, | Rad, | EGCG, a tea polyphenol, as a potential mitigator of hematopoietic radiation injury in mice |
| - | in-vivo, | Nor, | NA |
| 3235- | EGCG, | (-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells |
| - | in-vivo, | Cerv, | HeLa |
| 3236- | EGCG, | Buty, | Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate |
| - | in-vitro, | Colon, | RKO | - | in-vitro, | Colon, | HCT116 | - | in-vitro, | Colon, | HT29 |
| 3237- | EGCG, | (-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression |
| - | in-vivo, | AD, | NA |
| 3238- | EGCG, | Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications |
| - | Review, | Var, | NA |
| 3239- | EGCG, | (−)-Epigallocatechin Gallate, A Major Constituent of Green Tea, Poisons Human Type II Topoisomerases |
| - | in-vitro, | AML, | K562 |
| 3242- | EGCG, | Epigallocatechin gallate has pleiotropic effects on transmembrane signaling by altering the embedding of transmembrane domains |
| 3243- | EGCG, | (−)-Epigallocatechin-3-Gallate Inhibits Colorectal Cancer Stem Cells by Suppressing Wnt/β-Catenin Pathway |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid